No fungal vaccine has been approved for use in humans yet, but several are in active development, and recent breakthroughs suggest one could arrive within the next decade. The challenge is real: fungi are biologically much closer to human cells than bacteria or viruses, making it harder to design a vaccine that targets the pathogen without triggering problems in the host. Still, at least a handful of candidates have reached clinical trials, and the same mRNA technology behind COVID-19 vaccines is now being tested against deadly fungal infections in animal models.
The stakes are enormous. An estimated 6.5 million invasive fungal infections occur worldwide each year, causing roughly 3.8 million deaths. About 2.5 million of those deaths are directly attributable to the fungal infection itself. To put that in perspective, fungal diseases now kill more people annually than malaria or tuberculosis.
Why Fungal Vaccines Are So Hard to Make
Bacteria and viruses are fundamentally different from human cells, which gives vaccine designers clear molecular targets. Fungi are eukaryotes, just like us. They share a huge number of genes and cellular machinery with human cells, so finding a target that’s unique to the fungus and won’t cause collateral damage is genuinely difficult.
Fungi also shape-shift. Many species can switch between completely different physical forms depending on their environment, changing the composition of their outer cell wall and the proteins they display on their surface. A vaccine designed to recognize one form of the fungus may be useless against another. Some key proteins only appear during certain life stages, making them a moving target for the immune system.
Then there’s the immune response itself. Most vaccines work by training the body to produce antibodies, the kind of immune defense that works well against many viruses and bacteria. Fungal infections, however, require a different branch of immunity: cell-mediated responses driven primarily by specialized T cells. Effective fungal protection depends on activating specific helper T cell pathways (called Th1 and Th17 responses) that coordinate the body’s ability to kill fungal cells directly. Designing a vaccine that reliably triggers this type of immunity, rather than just producing antibodies, adds another layer of complexity.
Who Needs a Fungal Vaccine Most
The deadliest fungal infections don’t typically strike healthy people. They overwhelmingly affect those with weakened immune systems: organ transplant recipients on immunosuppressive drugs, people undergoing chemotherapy, and individuals with HIV/AIDS. Invasive aspergillosis alone affects over 2 million people annually, with a staggering 85% mortality rate. Candida bloodstream infections kill nearly 1 million people a year. Cryptococcal meningitis, which disproportionately hits people with advanced HIV, kills about 147,000 annually.
This creates a cruel paradox for vaccine developers. The people who need a fungal vaccine the most are the same people whose immune systems are least able to respond to one. Any successful fungal vaccine will need to generate protective immunity even in patients with compromised defenses, which is a much higher bar than most vaccines have to clear.
Vaccines Currently in Development
The most clinically advanced fungal vaccine candidate is NDV-3A, designed to prevent recurrent vaginal yeast infections caused by Candida. In a clinical trial, the vaccine reduced the frequency of infections in women who suffered from repeated episodes. NDV-3A works by targeting a protein on the surface of Candida cells, and it represents the clearest proof so far that a fungal vaccine can work in humans.
Valley fever, a lung infection caused by a soil fungus common in the American Southwest, is another major focus. The FDA has hosted dedicated workshops on Valley fever vaccine development, and multiple approaches are being pursued simultaneously: live-attenuated vaccines (using weakened versions of the fungus), recombinant protein vaccines, and newer mRNA and DNA platforms. Some of these candidates have already moved into testing in non-human primates.
A particularly promising line of research involves heat-killed yeast cells. Vaccines made from inactivated baker’s yeast have shown cross-protection against multiple dangerous fungi in animal studies, including Candida, Aspergillus, and Coccidioides (the Valley fever fungus). The protection comes from antibodies targeting sugar molecules shared across many fungal cell walls, combined with strong Th1 and Th17 cell responses.
mRNA Technology Changes the Picture
The mRNA vaccine platform, proven at massive scale during the COVID-19 pandemic, is now being applied to fungal pathogens. In a recent study, researchers built mRNA vaccines encoding proteins from Cryptococcus, the fungus responsible for cryptococcal meningitis. Mice vaccinated with three doses, spaced two weeks apart, developed high levels of antigen-specific antibodies that increased with each booster. When combined with a specific immune-boosting component, the vaccine protected the vast majority of mice from an otherwise lethal cryptococcal infection.
mRNA vaccines have a particular advantage for fungi. Because fungal cells are eukaryotic, their proteins have complex modifications that are hard to reproduce in a lab. When an mRNA vaccine instructs human cells to produce a fungal protein, those cells add similar modifications naturally, creating a more authentic version of the target. This means the immune system gets trained on something closer to the real thing.
The Promise of a Universal Fungal Vaccine
One of the most exciting directions in the field is the idea of a pan-fungal vaccine: a single shot that protects against multiple species at once. This isn’t as far-fetched as it sounds. Many dangerous fungi share common surface molecules, particularly a sugar called beta-1,3-glucan that forms the backbone of most fungal cell walls. A vaccine combining beta-1,3-glucan with a carrier protein has already shown it can protect mice from both Candida and Aspergillus infections.
Researchers have also identified a synthetic peptide called NXT-2, designed from sequences shared across Pneumocystis, Aspergillus, Candida, and Cryptococcus. In animal models, it reduced both illness and death from invasive infections caused by all four species. Other targets, including heat shock proteins that are highly conserved across the dimorphic fungi (species that switch between mold and yeast forms), could extend coverage even further.
What’s Holding Things Back
Beyond the biology, economics are a major barrier. Vaccine development costs hundreds of millions of dollars, and invasive fungal infections, despite their high death toll, affect a relatively small and hard-to-reach population compared to diseases like influenza or COVID-19. Pharmaceutical companies see a smaller potential market, which means less investment.
Clinical trials present their own headache. Because most people with healthy immune systems never develop invasive fungal disease, a vaccine trial would need to enroll large numbers of high-risk patients to demonstrate that it actually works. The disease is high-consequence but low-probability for any individual patient, meaning trials would need to be carefully targeted to transplant recipients, cancer patients, or others at elevated risk.
There’s a counterargument, though. Invasive fungal infections are so deadly and so expensive to treat that even a vaccine for a niche population could prove commercially viable. A vaccine that prevents aspergillosis in organ transplant recipients, or Valley fever in people living in endemic areas, wouldn’t need to reach billions of people to justify its development cost.